China Pharma Holdings, Inc. (CPHI) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

China Pharma Holdings, Inc. (CPHI) closed at USD 0.72 on 2026-10-14, a change of -59.1 % over the past year, with a market capitalization of USD 31.32M.

China Pharma Holdings, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

China Pharma Holdings, Inc. key figures

Previous close

USD 0.72 (2026-10-14)

1-year change

-59.1 %

Market cap

USD 31.32M

Enterprise value

USD 35.07M

P/E ratio (trailing)

-1.82

P/E ratio (forward)

n/a

EPS (trailing)

-0.40

EPS (forward)

n/a

PEG ratio

0.16

Price to book

0.82

Revenue growth

-7.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.26

Employees

215

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for China Pharma Holdings, Inc. and compare it with other stocks.